erectile%20dysfunction
ERECTILE DYSFUNCTION

Erectile dysfunction is the inability to attain and maintain an erection enough to have satisfactory sexual performance for ≥3 months.

It is when the patient complains of partial erection that could not attain vaginal penetration.

Complete loss of penile rigidity is uncommon.

Initial penile erections can penetrate but early detumescence occurs without ejaculation.

Diagnosis

  • Thorough sexual, medical & psychosocial history
    • Erectile dysfunction may be the first presentation of an underlying serious medical condition (eg hypertension, DM)

History

Sexual History

  • Patient consistently or recurrently is unable to maintain/attain an erection that is adequate for sexual satisfaction
  • May use validated psychometric questionnaires, eg International Index for Erectile Function (IIEF)

Physical Examination

  • Physical exam: Abdomen, penis, testicles, secondary sexual characteristics & lower extremity pulse, digital/rectal examination (DRE)
    • A DRE is not mandatory in erectile dysfunction but should be done in the presence of a genitourinary or protracted secondary ejaculatory symptoms

Laboratory Tests

  • Fasting blood glucose or HbA1c, lipid profile, testosterone assay to evaluate hypothalamic-pituitary-gonadal axis, urinary microscopy, etc as necessary
  •  Prostate-specific antigen (PSA) is measured before initiating & at regular intervals during testosterone therapy

Assessment

Treatment of erectile dysfunction in patients w/ CVD is associated w/ a small increase in the risk of myocardial infarction (MI) related to sexual activity independent of the method of treatment

CVD risk level:

  • High-risk - Should not receive therapy for sexual dysfunction until cardiac condition becomes stable
    • Unstable/refractory angina
    • Uncontrolled hypertension
    • SBP >180 mmHg
    • Left ventricular dysfunction (LVD) or CHF (NYHA class III, IV)
    • Recent MI or cardiovascular accident (CVA) w/in the past 2 wks
    • High-risk arrhythmias
    • Hypertrophic obstructive & other cardiomyopathies
    • Moderate-severe valvular disease
  • Intermediate-risk - Should be referred for further evaluation of cardiac status before receiving treatment
    • Recent MI or CVA (ie w/in the last 6 wks)
    • LVD/CHF (NYHA class II)
    • Asymptomatic but ≥3 risk factors for coronary artery disease (CAD) - excluding age & gender
    • Moderate stable angina
    • Murmur of unknown cause
    • Recurrent transient ischemic attacks (TIA)
    • Heart transplant
  • Low-risk - All 1st-line therapies may be considered
    • Asymptomatic coronary artery disease
    • Less than 3 risk factors for CAD (excluding age & gender)
    • Controlled hypertension
    • Mild, stable angina
    • Post-successful coronary revascularization
    • Uncomplicated previous myocardial infarction
    • Mild valvular heart disease
    • CHF (NYHA class I)
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
01 Nov 2017
High-grade serous carcinomas (HGSCs) of the pelvis, whether associated with serous tubal intra-epithelial carcinoma lesions or not, appear to have shared biologic origin in the distal fallopian tube, according to a recent study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.